Nurix Therapeutics Reports Strong Bexobrutideg Phase 1 Data, Initiates Pivotal Phase 2, and Plans Phase 3 Trial

summarizeSummary

Nurix Therapeutics reported its Q4 and FY 2025 financial results, highlighting a strong cash position of $592.9 million, bolstered by a recent $250 million offering. The company provided significant clinical updates for its lead asset, bexobrutideg, including compelling Phase 1 data from ASH 2025 showing an 83% objective response rate and 22.1 months progression-free survival in relapsed/refractory CLL. This data supports the ongoing pivotal Phase 2 DAYBreak study, with plans to initiate a global randomized confirmatory Phase 3 trial in the first half of 2026. These developments underscore the potential of bexobrutideg and provide a clear path towards regulatory approval, significantly de-risking the asset.

check_boxKey Events

• Positive Bexobrutideg Phase 1 Data

  Presented compelling Phase 1 results at ASH 2025 for bexobrutideg in relapsed/refractory CLL, demonstrating an 83% objective response rate and 22.1 months median progression-free survival.

• Pivotal Phase 2 Study Underway

  Initiated the DAYBreak pivotal Phase 2 single-arm study for bexobrutideg in relapsed/refractory CLL, with dose selection aligned with regulatory authorities. This follows the initial announcement on January 12, 2026.

• Confirmatory Phase 3 Trial Planned

  Plans to initiate a global randomized confirmatory Phase 3 trial (DAYBreak CLL-306) in the first half of 2026 to support full approval for bexobrutideg.

• Strong Financial Position

  Reported $592.9 million in cash, cash equivalents, and marketable securities as of November 30, 2025, following a $250 million underwritten offering in October 2025.

auto_awesomeAnalysis

Nurix Therapeutics reported its Q4 and FY 2025 financial results, highlighting a strong cash position of $592.9 million, bolstered by a recent $250 million offering. The company provided significant clinical updates for its lead asset, bexobrutideg, including compelling Phase 1 data from ASH 2025 showing an 83% objective response rate and 22.1 months progression-free survival in relapsed/refractory CLL. This data supports the ongoing pivotal Phase 2 DAYBreak study, with plans to initiate a global randomized confirmatory Phase 3 trial in the first half of 2026. These developments underscore the potential of bexobrutideg and provide a clear path towards regulatory approval, significantly de-risking the asset.